Wells Fargo & Company Cyclo Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$539,7800.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$437,0460.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$350,9167.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$111,2020.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$80,31618.16% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.16M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...